Please assess the completion status of the following clinical trial:

Trial Title: Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Currently enrolled and receiving treatment in INCB 18424-306 (NCT04052425) or INCB 18424-307 (NCT04057573) studies evaluating ruxolitinib cream in participants with vitiligo.~* Currently tolerating ruxolitinib cream in the parent study and no safety concerns per investigators judgment.~* Has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.~* Willingness and ability to comply with scheduled visits, treatment plans, and any other study procedures indicated in this protocol.~* Male and female participants must be willing to take appropriate contraceptive measures to avoid pregnancy or fathering a child.~* Ability to comprehend and willingness to sign an ICF or written informed consent of the parent(s) or legal guardian and written assent from the participant when possible.~Exclusion Criteria:~* Has been permanently discontinued from study treatment in the parent study for any reason.~* Participants with an uncontrolled intercurrent illness or any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the participant or compliance with the Protocol.~* Pregnant or breastfeeding woman.~* Participants who live with anyone participating in any current Incyte-sponsored ruxolitinib cream study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A : ruxolitinib cream (Type: EXPERIMENTAL): Participants who achieve complete or almost complete facial repigmentation (achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to ruxolitinib cream.
- Cohort A : Vehicle (Type: PLACEBO_COMPARATOR): Participants who achieve complete or almost complete facial repigmentation (ie, achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to vehicle cream.
- Cohort B : roxolitinib cream (Type: EXPERIMENTAL): Participants who did not achieve ≥ F-VASI90 at Week 52 of the parent studies will be assigned to Cohort B and will continue ruxolitinib cream.

Based on this trial design, predict the completion outcome and termination type (if applicable).